Medtronic Wins FDA Clearance for Reveal Linq Insertable Cardiac Monitor with TruRhythm Detection

Dublin–based Medtronic has gained FDA marketing clearance for its Reveal Linq insertable cardiac monitor with TruRhythm detection.

The device monitor allows physicians to continuously and wirelessly monitor a patient's heartbeat for up to three years and is approximately one-third the size of an AAA battery.

It is placed just beneath the skin through a small incision of less than 1cm in the upper left side of the chest and its presence is almost undetectable once the incision has healed.

The device communicates wirelessly with a bedside monitor that uploads device data to the Medtronic CareLink network. — Cynthia Jessup